Enzalutamide interactions
Full monograph for EnzalutamideCheck it against another medicine
Medicines
507 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Abemaciclib | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of abemaciclib and its pharmacologically active… | 6 sources — open the full entry |
| Abiraterone Acetate | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of abiraterone, which is partially metabolized by the… | 8 sources — open the full entry |
| Acalabrutinib | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of acalabrutinib, which is primarily metabolized by… | 7 sources — open the full entry |
| Alpelisib | Major | Metabolism | Coadministration of alpelisib with potent inducers of CYP450 3A4 may significantly reduce the plasma concentrations of alpelisib. The proposed mechanism, based… | 8 sources — open the full entry |
| Amiodarone Hydrochloride | Major | Synergy | Class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents can cause dose-related… | 45 sources — open the full entry |
| Amisulpride | Major | Synergy | Amisulpride can cause dose- and concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the… | 3 sources — open the full entry |
| Amlodipine Besilate | Major | Metabolism | Potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of calcium channel blockers, the majority of which are primarily metabolized… | 35 sources — open the full entry |
| Amlodipine Besilate + Atenolol | Major | Metabolism | Potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of calcium channel blockers, the majority of which are primarily metabolized… | 35 sources — open the full entry |
| Amlodipine Besilate + Atorvastatin | Major | Metabolism | Potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of calcium channel blockers, the majority of which are primarily metabolized…2 documented mechanisms | 47 sources — open the full entry |
| Amlodipine Besilate + Benazepril Hydrochloride | Major | Metabolism | Potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of calcium channel blockers, the majority of which are primarily metabolized… | 35 sources — open the full entry |
| Amlodipine Besilate + Olmesartan Medoxomil | Major | Metabolism | Potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of calcium channel blockers, the majority of which are primarily metabolized… | 35 sources — open the full entry |
| Amlodipine Besilate + Telmisartan | Major | Metabolism | Potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of calcium channel blockers, the majority of which are primarily metabolized… | 35 sources — open the full entry |
| Amlodipine Besilate + Valsartan | Major | Metabolism | Potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of calcium channel blockers, the majority of which are primarily metabolized… | 35 sources — open the full entry |
| Apixaban | Major | Metabolism | Coadministration with enzalutamide may decrease the plasma concentrations of apixaban. The proposed mechanism is enzalutamide-mediated induction of CYP450 3A4… | 7 sources — open the full entry |
| Apremilast | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of apremilast, which is primarily metabolized by the… | 5 sources — open the full entry |
| Arsenic Trioxide | Major | Synergy | Arsenic trioxide can cause QT interval prolongation and complete atrioventricular block. Theoretically, coadministration with other agents that can prolong the… | 4 sources — open the full entry |
| Artemether + Lumefantrine | Major | Metabolism · Synergy | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of artemether and lumefantrine, both of which are…3 documented mechanisms | 14 sources — open the full entry |
| Avatrombopag | Major | Metabolism | Concomitant use of avatrombopag with moderate to potent dual inducers of CYP450 2C9 and 3A4 may decrease the systemic exposure (AUC) of avatrombopag which may… | 4 sources — open the full entry |
| Axitinib | Major | Metabolism | Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of axitinib, which is primarily… | 9 sources — open the full entry |
| Bisoprolol Fumarate + Amlodipine Besilate | Major | Metabolism | Potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of calcium channel blockers, the majority of which are primarily metabolized… | 35 sources — open the full entry |
| Bortezomib | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may decrease the plasma concentrations and pharmacologic effects of bortezomib, which is primarily… | 10 sources — open the full entry |
| Brigatinib | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of brigatinib, which is partially metabolized by the… | 9 sources — open the full entry |
| Bupropion Hydrochloride | Major | Synergy | The use of bupropion is associated with a dose-related risk of seizures. The risk may be further increased when coadministered with selective serotonin… | 19 sources — open the full entry |
| Cabozantinib | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of cabozantinib, which is a substrate of the isoenzyme. | 7 sources — open the full entry |
| Capmatinib Hydrochloride | Major | Metabolism | Coadministration with strong or moderate CYP450 3A4 inducers may decrease the plasma concentrations and anti-tumor activity of capmatinib. The proposed… | 5 sources — open the full entry |
| Ceritinib | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of ceritinib, which is a substrate of the isoenzyme. | 3 sources — open the full entry |
| Citalopram Hydrobromide | Major | Synergy | Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may… | 15 sources — open the full entry |
| Clozapine | Major | Synergy | Clozapine has the potential to prolong QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can cause QT prolongation… | 13 sources — open the full entry |
| Crizotinib | Major | Metabolism | Coadministration with strong CYP450 3A4 inducers may decrease plasma concentrations and pharmacologic effects of crizotinib, which is primarily metabolized by… | 6 sources — open the full entry |
| Daclatasvir | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentration of daclatasvir, which is primarily metabolized by the… | 6 sources — open the full entry |
| Daclatasvir + Sofosbuvir | Major | Absorption · Metabolism | Coadministration with inducers of P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of sofosbuvir and other direct-acting antiviral…2 documented mechanisms | 17 sources — open the full entry |
| Darolutamide | Major | Metabolism | Coadministration with potent or moderate inducers of CYP450 3A4 that also induce P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of… | 6 sources — open the full entry |
| Dasatinib | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of dasatinib, which is primarily metabolized by the… | 11 sources — open the full entry |
| Deflazacort | Major | Metabolism | Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of 21-desdeflazacort, the active… | 6 sources — open the full entry |
| Dextromethorphan + Bupropion | Major | Synergy | The use of bupropion is associated with a dose-related risk of seizures. The risk may be further increased when coadministered with selective serotonin… | 19 sources — open the full entry |
| Elacestrant | Major | Metabolism | Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of elacestrant, which is primarily… | 1 sources — open the full entry |
| Erdafitinib | Major | Metabolism | Coadministration with potent inducers of CYP450 2C9 or 3A4 may decrease the plasma concentrations and therapeutic effects of erdafitinib. The mechanism is… | 2 sources — open the full entry |
| Escitalopram Oxalate | Major | Synergy | Escitalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may… | 13 sources — open the full entry |
| Everolimus | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may significantly decrease the blood concentrations and pharmacologic effects… | 6 sources — open the full entry |
| Fentanyl Citrate | Major | Metabolism | Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of opioids that are primarily metabolized by the isoenzyme such as… | 12 sources — open the full entry |
| Finerenone | Major | Metabolism | Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of finerenone, which is primarily… | 3 sources — open the full entry |
| Flibanserin | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of flibanserin, which is primarily metabolized by… | 3 sources — open the full entry |
| Gatifloxacin | Major | Synergy | Certain quinolones, including gatifloxacin and moxifloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically… | 28 sources — open the full entry |
| Gatifloxacin + Dexamethasone | Major | Metabolism · Synergy | Certain quinolones, including gatifloxacin and moxifloxacin, may cause dose-related prolongation of the QT interval in some patients. Theoretically…2 documented mechanisms | 39 sources — open the full entry |
| Haloperidol | Major | Synergy | Haloperidol can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may… | 14 sources — open the full entry |
| Ibrutinib | Major | Metabolism | Coadministration with inducers of CYP450 3A4 may significantly decrease the plasma concentrations of ibrutinib, which is primarily metabolized by the isoenzyme. | 4 sources — open the full entry |
| Iloperidone | Major | Synergy | Iloperidone may cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may… | 9 sources — open the full entry |
| Imatinib Mesylate | Major | Metabolism | Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of imatinib, which is primarily metabolized by the… | 10 sources — open the full entry |
| Indapamide + Amlodipine | Major | Metabolism | Potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of calcium channel blockers, the majority of which are primarily metabolized… | 35 sources — open the full entry |
| Iohexol | Major | Synergy | Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of… | 5 sources — open the full entry |
Conditions
Conditions in which Enzalutamide needs care, as documented in this source.
Kidney Diseases
ModerateEnzalutamide has not been assessed in patients with severe renal impairment or end-stage renal disease. Caution is advised if used on these patients. No initial dosage adjustment is required on patients with mild to moderate renal impairment.
1 source
- "Product Information. Xtandi (enzalutamide)." Astellas Pharma US, Inc (2012):
Seizures
ModerateSeizures occurred in 0.5% of patients receiving enzalutamide in clinical trials. Patients with predisposing factors for seizures were generally excluded. Caution is advised if using in patients with possible predisposing factors such as history of seizures, history of trauma or head injury, cerebrovascular accident or transient ischemic attack, Alzheimer's disease, meningioma or brain tumor or infection, and any unexplained loss of consciousness in the past 12 months. Enzalutamide should be discontinued permanently in any patient who develops a seizure during treatment.
1 source
- "Product Information. Xtandi (enzalutamide)." Astellas Pharma US, Inc (2012):
Therapeutic duplication
Drug classes that overlap with Enzalutamide, so taking both doubles up the same effect. This source publishes no per-row citations for duplication.
antineoplastic hormones
The recommended maximum number of medicines in the 'antineoplastic hormones' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'antineoplastic hormones' category.
Example product in the source data (US market): Letrozole/ribociclib